Department of Neurosurgery, Juntendo University Shizuoka Hospital, 1129 Nagaoka, Izunokuni, Shizuoka, 410-2295, Japan.
Department of Neurosurgery, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima, Tokyo, 177-8521, Japan.
Sci Rep. 2024 May 25;14(1):12009. doi: 10.1038/s41598-024-62717-5.
Spontaneous intracerebral hemorrhage (SICH) remains a devastating form of stroke. Prior use of antiplatelets or warfarin before SICH is associated with poor outcomes, but the effects of direct oral anticoagulants (DOACs) remain unclear. This study aimed to clarify trends in prior antithrombotic use and to assess the associations between prior use of antithrombotics and in-hospital mortality using a multicenter prospective registry in Japan. In total, 1085 patients were analyzed. Prior antithrombotic medication included antiplatelets in 14.2%, oral anticoagulants in 8.1%, and both in 1.8%. Prior warfarin use was significantly associated with in-hospital mortality (odds ratio [OR] 5.50, 95% confidence interval [CI] 1.30-23.26, P < 0.05) compared to no prior antithrombotic use. No such association was evident between prior DOAC use and no prior antithrombotic use (OR 1.34, 95% CI 0.44-4.05, P = 0.606). Concomitant use of antiplatelets and warfarin further increased the in-hospital mortality rate (37.5%) compared to warfarin alone (17.2%), but no such association was found for antiplatelets plus DOACs (8.3%) compared to DOACs alone (11.9%). Prior use of warfarin remains an independent risk factor for in-hospital mortality after SICH in the era of DOACs. Further strategies are warranted to reduce SICH among patients receiving oral anticoagulants and to prevent serious outcomes.
自发性脑出血(SICH)仍然是一种破坏性的中风形式。SICH 之前使用抗血小板药物或华法林与不良预后相关,但直接口服抗凝剂(DOAC)的效果仍不清楚。本研究旨在阐明 SICH 之前抗血栓形成药物使用的趋势,并使用日本多中心前瞻性登记处评估 SICH 之前使用抗血栓形成药物与住院死亡率之间的关联。共分析了 1085 例患者。之前的抗血栓药物治疗包括抗血小板药物 14.2%,口服抗凝剂 8.1%,两者均有 1.8%。与未使用抗血栓形成药物相比,SICH 之前使用华法林与住院死亡率显著相关(比值比 [OR] 5.50,95%置信区间 [CI] 1.30-23.26,P < 0.05)。与未使用抗血栓形成药物相比,SICH 之前使用 DOAC 与无抗血栓形成药物之间无明显关联(OR 1.34,95%CI 0.44-4.05,P = 0.606)。与单独使用华法林相比,抗血小板药物和华法林的联合使用进一步增加了住院死亡率(37.5%),但与单独使用 DOAC 相比,抗血小板药物加 DOAC 无明显关联(8.3%)。在 DOAC 时代,SICH 后华法林的使用仍然是住院死亡率的独立危险因素。需要进一步采取策略,减少接受口服抗凝剂治疗的患者的 SICH,并预防严重后果。